Plain-English translation of NCT07145008 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a new injection called suprachoroidal triamcinolone can help reduce swelling in the center of the retina (called macular edema) caused by non-infectious uveitis — a condition where the eye becomes inflamed. The treatment is specifically for people who did not improve after receiving a standard steroid injection around the eye. Researchers want to see if this medication can improve vision and reduce the swelling within three months.
Some people with eye inflammation and retinal swelling don't respond well enough to the standard steroid injection. This trial exists to find out whether placing the medication directly in a deeper layer of the eye might work better for these patients.
You likely qualify if…
You likely don't qualify if…
You will have an initial appointment where your vision and eye will be checked and a detailed retinal scan will be taken. Then you will receive one injection of the medication in a sterile operating room setting with numbing drops. After that, you will return for follow-up visits at about one month and three months to repeat your vision tests and retinal scans to see if the swelling has improved. You should contact the clinic right away if you experience pain, redness, new floaters, or worsening vision between visits.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Iraq